|
The U.K. Pharmacovigilance Market Size is Expected to Reach USD 510.37 Million by 2028
Thursday, November 11, 2021
DUBLIN, Nov. 3, 2021 /PRNewswire/ -- The "U.K. Pharmacovigilance Market Size, Share & Trends Analysis Report By Service Provider (Contract Outsourcing, In-house), By Product Life Cycle, By Type, By Process Flow, By Therapeutic Area, By End-use, And Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
The U.K. pharmacovigilance market size is expected to reach USD 510.37 million by 2028, according to a new report by the publisher It is expected to expand at a CAGR of 11.9% from 2021 to 2028.
The increasing outsourcing and externalization of clinical trials by the majority of the pharmaceutical and biotechnological companies, regulatory mandates on clinical trial conduct, and post-marketing vigilance are likely to drive the market at an unprecedented rate throughout the forecast period.
Moreover, the introduction of technologically advanced and user-friendly software systems, such as cloud-based PV platforms, is anticipated to drive the market in the coming years.
In June 2017, Genpact launched Pharmacovigilance Artificial Intelligence ("PVAI") solution to alter drug safety data management and reporting. While in December 2020, the Medicines and Healthcare products Regulatory Authority (MHRA) signed a deal with Genpact for obtaining the PVAI tool for USD 2.07 million. In that way, the U.K. became one of the world's first drug regulators to usage an AI tool to record and process adverse drug reactions.
Throughout the past decade, the augmented usage of numerous expedited review approaches and other developments have led to a decline in the time taken to bring new drugs to the market. While this hastening has led to more quick access for patients, it also upsurges the risk of adverse drug reactions being spotted for the first time when the product is already in the market, leading to the higher demand for post-approval safety surveillance studies and related actions. This is eventually supporting the overall market growth.
Although COVID-19 is forcing many medical device and drug developers to revise their approach to handle the crisis, integrating best practices within clinical trial procedures and adoption of virtual trials can support the constant progress of therapeutics in the pandemic environment. For instance, PPD deployed remote site-monitoring tools to replace on-site visits for COVID-19safety, enabling trial continuation.
An increase in R&D and the adoption of new technologies in clinical research are likely to further drive the market. For instance, in April 2020, IBM launched AI-based technologies and COVID-19 high-performance computing consortium to assist research and health communities and accelerate the discovery of medical insights and treatments for COVID-19.
The rising number of contract research organizations and increased demand for outsourcing services are expected to fuel the market competition among market players in the near future. Key participants are involved in continuous product development, partnerships, mergers, and acquisitions to augment market penetration. For instance, in march 2021, ProPharma Group acquired Diamond Pharma Services. This acquisition will help in solidifying ProPharma Group's position as the leading global provider of regulatory, compliance, pharmacovigilance, and medical information services.
U.K. Pharmacovigilance Market Report Highlights
-- By product life cycle, phase IV dominated the market in 2020 phase IV
clinical studies are complex in design and large in scale. Besides, this
is an imperative phase of clinical trials as unanticipated adverse drug
reactions can be spotted in this phase
-- In terms of service provider, contract outsourcing held a dominant share
in 2020 owing to the rapidly emerging CROs providing end-to-end clinical
trial solutions and outsourcing trends in the pharmaceutical,
biotechnology, and medical devices industries. In January 2018, Concept
Life Sciences and Alderley Analytical signed a partnership contract to
deliver high-value bio analytical and DMPK study services
-- Based on type, spontaneous reporting held the largest share of over
30.0% in 2020 owing to its wide usage in the detection of new, serious,
and rare ADRs and its popularity as an efficient and inexpensive method.
Spontaneous reporting during the post marketing phase produces most drug
safety data, yet more than clinical trials during drug development,
thereby boosting demand
-- On the basis of process flow, the case data management segment is
expected to witness the fastest growth over the forecast period. The
adverse event information can be generated from various modes, such as
post-marketing programs, clinical trials, spontaneous reports, and
literature. Some of the data management software include PV-Works Human,
ClinSource, and Oracle
-- The oncology therapeutic area segment held the largest share of over
25.0% in 2020. Monitoring the safety of cancer drugs is very important
due to the associated side effects, which is propelling the demand for
pharmacovigilance services
-- The biotechnology companies end-use segment is anticipated to exhibit
the highest CAGR of 12.6% over the forecast period. The number of U.K.
biotechnology corporations has boomed, growing by 65% since 2016
Key Topics Covered:
-- Chapter 1 Research Methodology & Scope
-- Chapter 2 Executive Summary
-- Chapter 3 Pharmacovigilance Market Variables, Trends & Scope
-- Chapter 4 COVID-19 Impact Analysis
-- Chapter 5 Pharmacovigilance Market: Service Provider Estimates & Trend
Analysis
-- Chapter 6 Pharmacovigilance Market: Type Estimates & Trend Analysis
-- Chapter 7 Pharmacovigilance Market: Product Life Cycle Estimates & Trend
Analysis
-- Chapter 8 Pharmacovigilance Market: Process Flow Estimates & Trend
Analysis
-- Chapter 9 Pharmacovigilance Market: Therapeutic Area Estimates & Trend
Analysis
-- Chapter 10 Pharmacovigilance Market: End-use Estimates & Trend Analysis
-- Chapter 11 Competitive Outlook
-- Chapter 12 Company Profiles
-- Chapter 13 Winning Strategies
Companies Mentioned
-- Accenture
-- IQVIA
-- Cognizant
-- IBM Corporation
-- ArisGlobal
-- ICON Plc.
-- Capgemini
-- TAKE Solutions
-- PAREXEL International Corporation
-- BioClinica, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/d98ce8
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:https://www.prnewswire.com/news-releases/the-uk-pharmacovigilance-market-size-is-expected-to-reach-usd-510-37-million-by-2028--301415228.html
SOURCE Research and Markets
|
|
|
|
|
|
 |
Asetek - Mandatory Notification of Trade | Jan 22, 2026
|
|
BC.GAME to Host "Stay Untamed" Night During Abu Dhabi's Packed Web3 Summit Week | Jan 22, 2026
|
|
Tomorrowland Brings the Magic to Shanghai for a Spectacular First Indoor Edition in China | Jan 22, 2026
|
|
Rent Manager Earned Best Real Estate Software Product Award and Multiple Review Badges from G2 Platform | Jan 22, 2026
|
|
Auburn University's Applied Research Institute Expands Advanced Manufacturing Capabilities with CF3D Enterprise Cell | Jan 22, 2026
|
|
California Divorce Mediation Center Unveils Modern Website Redesign | Jan 22, 2026
|
|
AMPERA ANNOUNCES LOCATION FOR GLOBAL HEADQUARTERS | Jan 22, 2026
|
|
Gemmy Alerts Customers: Fake Websites Target Holiday Decorators | Jan 22, 2026
|
|
Immutable Announces First Co-Founder-Hosted Live Webinar: How to Dominate Your Steam Launch | Jan 22, 2026
|
|
Culture and tourism sectors thrive in Xiamen | Jan 22, 2026
|
|
|
|
